SanegeneBio is a global biotech with a singular vision: Best-in-class RNAi medicines. We are focused on discovering and developing best-in-class genetic medicines for obesity, cardiometabolic, and autoimmune diseases using RNA interference (RNAi) technology.
Our proprietary technology platform, LEAD™ (Ligand and Enhancer Assisted Delivery), enables tissue-specific silencing of disease-driving genes in the liver, adipose tissue, muscle, and immune cells—achieved through safe, infrequent subcutaneous dosing. SanegeneBio is committed to advancing transformative RNAi therapies that address global unmet medical needs.
We envision a future where RNAi medicines are a cornerstone of standard-of-care for addressing large and diverse patient populations.
Suzhou R&D Center established, first IND approved, $80M additional financing secured
First development program leveraging advanced LEAD technology initiated, first Phase 2 clinical trial initiated
US Headquarters established, first IND-enabling studies completed
Phase 1 trials initiated in Australia, New Zealand and China for 3 programs
